Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT

International Journal of Cancer

Volumn 136, Issue 5, 2015, Pages E326-E339

  Doberstein, Kai ^a   Harter, Patrick N ^b   Haberkorn, Uwe ^c   Bretz, Niko P ^a   Arnold, Bernd ^a   Carretero, Rafael ^a   Moldenhauer, Gerhard ^a   Mittelbronn, Michel ^b   Altevogt, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

EMT; Immunotherapy; L1CAM; Transgenic mice

Indexed keywords

ANTINEOPLASTIC AGENT; IODINE 125; MONOCLONAL ANTIBODY L1CAM; UNCLASSIFIED DRUG; MESSENGER RNA; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE L1; RADIOACTIVE IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; KIDNEY COLLECTING TUBULE; L1CAM GENE; LOW DRUG DOSE; MELANOMA; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; TRANSGENE; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; PANCREATIC NEOPLASMS; PATHOLOGY; RADIOIMMUNOTHERAPY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IODINE RADIOISOTOPES; MELANOMA; MICE; MICE, TRANSGENIC; NEURAL CELL ADHESION MOLECULE L1; PANCREATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84918788735     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29222     Document Type: Article

References (45)

1. Moos M, Tacke R, Scherer H, et al. Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature 1988;334:701-3.
2. Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 2003;362:869-75.
3. Kaifi JT, Reichelt U, Quaas A, et al. L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 2007;20:1183-90.
4. Sebens Muerkoster S, Werbing V, Sipos B, et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007;26:2759-68.
5. Ben QW, Wang JC, Liu J, et al. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol 2010;17:2213-21.
6. Huszar M, Pfeifer M, Schirmer U, et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 2010;220:551-61.
7. Bondong S, Kiefel H, Hielscher T, et al. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-kappaB activation. Ann Oncol 2012;23:1795-802.
8. Boo YJ, Park JM, Kim J, et al. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol 2007;14:1703-11.
9. Mechtersheimer S, Gutwein P, Agmon LN, et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001;155:661-74.
10. Gavert N, Conacci-Sorrell M, Gast D, et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005;168:633-42.
11. Meier F, Busch S, Gast D, et al. The adhesion molecule L1 (CD171) promotes melanoma progression. Int J Cancer 2006;119:549-55.
12. Arlt MJ, Novak-Hofer I, Gast D, et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 2006;66:936-43.
13. Wolterink S, Moldenhauer G, Fogel M, et al. Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res 2010;70:2504-15.
14. Fischer E, Grunberg J, Cohrs S, et al. L1-CAMtargeted antibody therapy and (177) Lu-Radioimmunotherapy of disseminated ovarian cancer. Int J Cancer 2012;130:2715-21.
15. Farady CJ, Sellers BD, Jacobson MP, et al. Improving the species cross-reactivity of an antibody using computational design. Bioorg Med Chem Lett 2009;19:3744-7.
16. Kato M, Takahashi M, Akhand AA, et al. Transgenic mouse model for skin malignant melanoma. Oncogene 1998;17:1885-8.
17. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984;44:717-26.
18. Kiefel H, Bondong S, Erbe-Hoffmann N, et al. L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression. Oncogene 2010;29:4766-78.
19. Gutwein P, Oleszewski M, Mechtersheimer S, et al. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 2000;275:15490-7.
20. Bretz NP, Salnikov AV, Doberstein K, et al. CD24 expression alters leukocyte trafficking to the colon. Immunol Lett 2014;161:140-8.
21. Gast D, Riedle S, Kiefel H, et al. The RGD integrin binding site in human L1-CAM is important for nuclear signaling. Exp Cell Res 2008;314:2411-8.
22. Huszar M, Moldenhauer G, Gschwend V, et al. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol 2006;37:1000-8.
23. Nolte C, Moos M, Schachner M. Immunolocalization of the neural cell adhesion molecule L1 in epithelia of rodents. Cell Tissue Res 1999;298:261-73.
24. Martini R, Schachner M. Immunoelectron microscopic localization of neural cell adhesion molecules (L1, N-CAM, and myelin-associated glycoprotein) in regenerating adult mouse sciatic nerve. J Cell Biol 1988;106:1735-46.
25. Rathjen FG, Schachner M. Immunocytological and biochemical characterization of a new neuronal cell surface component (L1 antigen) which is involved in cell adhesion. EMBO J 1984;3:1-10.
26. Schafer MK, Altevogt P. L1CAM malfunction in the nervous system and human carcinomas. Cell Mol Life Sci 2011;67:2425-37.
27. Helbert MJ, Dauwe SE, De Broe ME. Flow cytometric immunodissection of the human distal tubule and cortical collecting duct system. Kidney Int 2001;59:554-64.
28. Doberstein K, Wieland A, Lee SB et al. L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. Carcinogenesis 2011;32:262-70.
29. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005;310:1510-2.
30. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42.
31. Schafer H, Dieckmann C, Korniienko O, et al. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett 2012;319:66-82.
32. Schafer H, Geismann C, Heneweer C, et al. Myofibroblastinduced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent. Carcinogenesis 2012;33:84-93.
33. Zeimet AG, Reimer D, Huszar M, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst 2013;105:1142-50.
34. Bergmann F, Wandschneider F, Sipos B, et al. Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol Rep 2010;24:909-15.
35. Geismann C, Morscheck M, Koch D, et al. Upregulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slugdependent: role in malignant transformation of pancreatic cancer. Cancer Res 2009;69:4517-26.
36. Kugler S, Bocker K, Heusipp G, et al. Pertussis toxin transiently affects barrier integrity, organelle organization and transmigration of monocytes in a human brain microvascular endothelial cell barrier model. Cell Microbiol 2007;9:619-32.
37. Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010;18:160-70.
38. Novak-Hofer I, Amstutz HP, Macke HR, et al. Cellular processing of copper-67-labeled monoclonal antibody chCE7 by human neuroblastoma cells. Cancer Res 1995;55:46-50.
39. Novak-Hofer I. The L1 cell adhesion molecule as a target for radioimmunotherapy. Cancer Biother Radiopharm 2007;22:175-84.
40. Long KE, Asou H, Snider MD, et al. The role of endocytosis in regulating L1-mediated adhesion. J Biol Chem 2001;276:1285-90.
41. Diessner J, Bruttel V, Stein RG, et al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis 2014;5:e1149.
42. Gavert N, Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 2008;14:199-209.
43. Misra A, Pandey C, Sze SK, et al. Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT). PLoS One 2012;7:e49766.
44. Zhang Z, Dong Z, Lauxen IS, et al. Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype. Cancer Res 2014;74:2869-81.
45. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52.